KR100772007B1 - An aloe composition for macrophage activation or anticancer - Google Patents

Abstract

The present invention relates to macrophage activation or anticancer efficacy of Modified Aloe Polysaccharides (MAP), and provides an aloe composition containing a MAP having a molecular weight range of 5 to 400 KDa having an optimal macrophage activation or anticancer efficacy.

Aloe, MAP

Description

An aloe composition for macrophage activation or anticancer

1 is a diagram showing the immune activity of MAP on RAW 264.7 cells,

2 is a diagram showing an immunophenotype analysis of RAW 264.7 cells cultured with MAP,

3 is a diagram showing the phagocytosis of RAW 264.7 cells stimulated with MAP,

4 is a diagram showing the relationship between molecular weight size-macrophage activation of MAP,

5 is a diagram showing a phagocytic assay for the anticancer activity of MAP.

The present invention relates to macrophage activation or anticancer efficacy of Modified Aloe Polysaccharides (MAP), and provides an aloe composition containing a MAP having a molecular weight range of 5 to 400 KDa having an optimal macrophage activation or anticancer efficacy.

As used herein, Modified Aloe Polysaccharides (MAP) refer to processed aloe polysaccharides isolated from cellulase treated aloe gels and have a low molecular weight of 80 KDa average molecular weight.

The total amount of polysaccharides contained in the aloe juice is about 10% by dry weight, and the molecular weight of these polysaccharides varies widely, and the average molecular weight is known to be 2 million Da or more. These polysaccharides have been known to have various immunomodulatory effects not only in vitro but also in vivo ([1] Reynolds T, Dweck AC.Aloe vera gel leaf: a review update. J Ethnopharmacol 1999; 68: 3-37). Controversy still exists regarding the molecular weight of the aloe polysaccharides, which exhibit the best immunostimulating activity.

Acemannan (Carrisyn ^TM ), the most well-known natural polysaccharide isolated from aloe vera juice, is an acetylated galactomannan linked through β- (1,4) bonds. It is known to have wound healing effects. It has been reported that acemannan is completely healed or significantly reduced when administered abdominally to animals with tumors. Acemannan is shown to increase response to homologous antigens in the lymphocyte mixed culture test, to produce macrophages by producing immunocytokines such as IL-6 and TNF-α, and to increase the production and phagocytosis of NO by macrophages. Acemannan's anti-cancer efficacy is shown to occur through the host's defense system (2) Manna S, McAnalley BH.Determination of the position of the O-acetyl group in a b- (1,4) -mannan ( acemannan) from Aloe barbadensis Miller.Carbohydr Res 1993; 241: 317-319). (3) Peng SY, Norman J, Curtin G, Corrier D, McDaniel HR, et al.Decreased mortality of Norman Murine Sarcoma in mice treated with the immunomodulator, acemannan.Mol Biother 1991; 3: 79-87. [4] Harris C, Pierce K, King G, Yates KM, Hall J, Tizard I. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms.Molec Biother 1991; 3: 207-213. [5] King GK, Yates KM, Greenlee PG, Pierce KR, Ford CR, et al. The effects of acemannan immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas.J AM Anim Hosp Assoc 1995; 31: 439-447.) Carrington Lavoratories (Irving, Tex CARN, developed in), consists of an acemannan polysaccharide with an average molecular weight of 1,000 KDa.

Recently, polysaccharides with molecular weights ranging from 4,000 KDa to 7,000 KDa, named aloe ride, have been isolated from Aloe Vera. It has also been found to have immunopotentiating effects ([6] Pugh N, Ross SA, El Sohly MA, Pasco). DS.Characterization of aloride, a new high-molecular-weight polysaccharide from Aloe vera with potent immunostimulatory activity.J Agric Food Chem 2001; 49: 1030-1034).

The treatment of aloe juice with cellulase reduces the viscosity and changes to a form that can be easily processed. However, the problem has been raised because the molecular weight of the aloe polysaccharide will also be reduced, thereby reducing the physiological activity.

However, unlike acemannan or aloeride, MAP, a 'low molecular weight' polysaccharide isolated from 'cellulase treated' aloe juice, has been reported to show stronger physiological activity than polysaccharides with an average molecular weight of 2,000 KDa before processing. (7) Qui Z, Jones K, Wylie M, Orndorff S. Modified Aloe barbadensis polysaccharide with immunoregulatory activity.Planta Med 2000; 66: 152-156. However, this document differs from the present invention in that it reveals the protective effect of the MAP particularly against ultraviolet rays.

Meanwhile, the average molecular weight range of 70 KDa ([8] Madis VH, Omar MM, Madis V. Aloeferon isolation, manufacturing and its applications.US Patent 1989; 4,861,761.) And the range of 420 KDa to 520 KDa ([9] Farkas A, Mayer A. Polysaccharides from RA juice polysaccharide from the juice of the aloe plant for treatment of wounds.US Patent 1968; 3,362,951. ] Is different from the present invention in that it discloses a wound healing effect.

Although various studies on the immunomodulatory efficacy of aloe polysaccharides have been conducted by various researchers as described above, the correlation between the molecular weight of the aloe polysaccharides and the immunomodulatory efficacy has not been elucidated yet.

Therefore, determining the optimal molecular weight range of MAP having the highest molecular activity while having a low molecular weight is very important industrially in that it simultaneously provides ease of processing and excellence in effect.

The present inventors investigated the efficacy according to the molecular weight of the MAP, revealed a molecular weight range that shows the optimal macrophage activation or anti-cancer effect.

The present invention provides an aloe composition having excellent macrophage activation or anticancer effect. In particular, the present invention provides a composition for macrophage activation or anticancer containing MAP (Modified Aloe Polysaccharides) of 5 KDa to 400 KDa. Preferably the aloe in the composition is aloe vera. The composition may be a pharmaceutical composition or a dietary supplement. The present invention also provides a method for preparing MAP of 5 KDa to 400 KDa.

Hereinafter, the present invention will be described in more detail.

In the present invention, the aloe polysaccharide MAP treated with cellulase was tested by fractionation by molecular weight to find the molecular weight range showing the highest macrophage activation or anticancer efficacy.

The aloe gel was treated with cellulase and then activated carbon was used to remove anthraquinones and pigments. Then, the dialysis membrane was placed in a dialysis membrane having a dialysis range of 1 KDa, and purified by distilled water with sufficient dialysis.

The dry powder of aloe gel treated with cellulase was extracted using 80% ethanol and then centrifuged to obtain a precipitate. This polysaccharide precipitate (G2E1) was obtained from a protein-free polysaccharide sample (G2E1D) through a DEAE Sephacel column, and the G2E1D was fractionated to a molecular weight of 400 KDa or more and 400 KDa or less by a Sephacryl S400 column. . At this time, to determine the elution time of more than 400 KDa and less than the separation of the standard mixture of broaddextran molecular weight under the same conditions before sample separation was used HPLC and RI detector. Below 400 KDa was again centrifuged using 5 KDa ultrafiltration to fractionate more than 5 KDa and less than 5 KDa.

As a result of the activity test on the obtained polysaccharide fraction of 400 KDa or more, 5 KDa to 400 KD and 5 KDa or less, the present inventors found that MAP having a molecular weight of 5 KDa to 400 KDa has excellent immunomodulation efficacy and anticancer effect. First revealed.

Accordingly, the present invention provides aloe composition for macrophage activation or anticancer containing MAP having a molecular weight of 5 KDa to 400 KDa.

The macrophage activation or anti-cancer aloe composition containing the MAP of the present invention may be a pharmaceutical composition or a dietary supplement.

The compositions of the present invention can be formulated by methods known in the pharmaceutical art and can be administered orally or parenterally.

Therefore, the compositions of the present invention can be formulated into conventional pharmaceutical preparations such as liquids, capsules, tablets and the like by mixing with the aloe extract itself or with a pharmaceutically acceptable carrier, excipient and the like.

Pharmaceutical compositions for oral administration include solid dosage forms, such as capsules, tablets, or the like, optionally prepared as conventional means, together with pharmaceutically acceptable excipients such as binders, fillers, glidants, disintegrants, or wetting agents. , Liquid formulations such as solutions, syrups or suspensions containing non-aqueous solvents and preservatives.                     

Compositions of the invention for parenteral administration can be formulated by conventional methods for administration by injection, typically intravenous, intramuscular, intraperitoneal or subcutaneous injection.

In addition, the MAP of the present invention can be added to foods to produce macrophage activation or anti-cancer health functional foods.

In this case, the health functional food refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients having useful functions for the human body.

The dosage of MAP which is an active ingredient in the composition of the present invention is in the range of 10 mg / kg to 1,000 mg / kg per day. However, the dosage of MAP as the active ingredient should be determined in consideration of various factors such as the route of administration, the severity of the patient being treated, age, sex, and weight, and the scope of the present invention is limited by the dosage. It should not be.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are only presented for the purpose of illustrating the present invention and should not be construed as limiting the scope of the present invention in any way.

Example

Experimental material

Aloe juice powder sample, which is a raw material of aloe polysaccharide used in this study, was concentrated to 200: 1 weight by drying the juice removed from the aloe vera shell and was supplied from Aloecorp (Harlingen, TX, USA).                     

Reagents and Instruments

The experimental equipment used in this experiment is as follows. HPLC was used HITACHI (pump; L-7100, detector; L-7490, interface; D-7000, column oven; L-7300, Autosampler; L-7200). FPLC was used AKTA series (Amersham phamacia biotech), and a freeze dryer of 20 L (Ilshin Lab co., Ltd) capacity. The centrifuge used Beckman Coulter ^TM (Allegra ^TM 60R) and the rotary vacuum evaporator EYELA (NN series). Sephacryl S400 resin and DEAE Sephacel resin (Amersham Bioscience) were used as adsorbents for column chromatography. Ultrafiltration was performed using 5K Amicon ultra (Millipore) and the HPLC column used for analysis was BioSep-SEC-S400 (Phenomenex).

The organic solvent for extraction was made by Deoksan (Seoul, Korea), and the first organic reagent was used for separation. Broad dextran (Phenomenex, ALO-2772) was used as a standard.

Experiment method

Separation of MAP

Cellulase was added to 12 mg / L of aloe gel and treated for 2 hours at room temperature, followed by 30 minutes at 90 ° C to terminate the reaction. Anthraquinones and pigments contained were adsorbed and removed by adding activated carbon at 1 mg / mL, stirring for 1 hour, and centrifuging. The MAP thus obtained was purified by a method of sufficiently dialysis using distilled water after putting it in a dialysis membrane having a dialysis range of 1 KDa.

After the addition of 80% ethanol at a rate of 50 ml per g dry powder of aloe gel treated with cellulase and stirred for 1 hour, centrifugation was performed at 3000 rpm, 15 minutes, 25 ℃. After centrifugation, a small amount of water was added to the precipitate, and the mixture was left at -70 ° C for one day and then lyophilized. This lyophilisate was named G2E1.

20 g of G2E1 was dissolved in a small amount of 20 mM Tris-HCl (pH 7.4) buffer and then filtered to 0.45 mu m. Samples were bound at a flow rate of 4 ml / min using FPLC with a DEAE Sephacel column (6 cm × 30 cm) attached. 20 mM Tris-HCl (pH 7.4) buffer was flowed, and the polysaccharide solution from which protein was not bound to the column resin was removed under reduced pressure until only a small amount of solution remained. It was left at -70 ℃ for one day and then lyophilized. This lyophilisate was named G2E1D.

Broaddextran 7.2KDa, 16.2KDa, 230KDa, 520KDa was mixed with 10mg each to perform a Sephacryl S400 column (4 cm X 100 cm). 100% distilled water was used as the eluting solvent and 5 ml per test tube was aliquoted. Each standard mixed solution elution fraction and each standard were analyzed by HPLC to determine the elution volume corresponding to more than 400KDa and less than 400KDa. At this time, Biosep-SEC column and RI detector were used as HPLC conditions, and distilled water was used as a mobile phase.

After dissolving 4 g of G2E1D in 100% distilled water, the polysaccharide was fractionated by molecular weight using Sephacryl S400 column. The conditions were performed in the same manner as in the standard product. Referring to the HPLC data and the elution volume of the standard product divided into more than 400 KDa and less than 400 KDa, and more than 400 KDa was dried under reduced pressure until only a small amount of solution remains. Below 400 KDa was centrifuged at 3000 rpm, 30 minutes, 20 ℃ using 5 KDa ultrafiltration and fractionated to more than 5 KDa. Acetone was added to remove the buffer contained in the solution of 5 KDa or less, and then only polysaccharide precipitated by centrifugation at 1000 rpm, 10 minutes, and 20 ° C was used. After drying under reduced pressure until only a small amount of solution remained, the resultant was left at -70 ° C for one day and then lyophilized.

As a result, the polysaccharide was fractionated to 400 KDa or more (G2E1DS3), 400 KDa to 5 KDa or more (G2E1DS2), and 5 KDa or less (G2E1DS1), and yields of each fraction were as follows. ; G2E1, 50.3%; G2E1D, 39.7%; G2E1DS1, 5.6%; G2E1DS2, 2.6%; G2E1DS3, 12.5%.

Cell culture

Cultures of RAW 264.7 cells consisted of 10% bovine serum (Hyclone), 50 μM 2-mercaptoethanol (SIGMA), 100 μg / ml penicillin G (Bio-whittaker) and 100 units / ml streptomycin (Bio-whittaker). DMEM (Dulbecco's modified Eagle's medium) was added and cultured in an incubator at 37 ° C. (5% CO ₂ /95% atmosphere).

Proliferation assay

RAW 264.7 cells were added to the 96-well microtiter plate at 2 × 10 ⁴ cells / well, and then samples were added to each well by concentration and incubated for 42 hours. Proliferation of RAW 264.7 is ^[3 H] - thymidine (0.5 μCi / well) was added to each well of 6 hours and then further incubated ^[3 H] - thymidine in Corporation ^([3 H] -thymidine incoporation) Measured by the method.

Immunophenotyping

Macrophage cultured with aloe polysaccharides were used to determine the expression level of cell surface antigens based on co-stimulatory molecules such as class II MHC molecules, B7-1, B7-2, CD40, and ICAM-1. It was analyzed by (flow cytometry). Monoclonal antibodies used in the experiments: anti-CD40 (clone 3/23), anti-ICAM-1 (clone 3E2), anti-I-Ab (clone AF6-120.1), anti-B7-1 (clone 16-10A1 ), Anti-B7-2 (clone GL1) and isotype-matched control antibodies were purchased from Pharmingen (San Diego, Calif.) And used for experiments. After staining, the cells were fixed with 1% ρ-formaldehyde, and then analyzed on 10,000 live cells using FACS caliber (Becton-Dickinson).

Grasping power

The phagocytosis of RAW 264.7 cells by aloe polysaccharides was measured using microspheres in the form of particles containing fluorescein isothiocyante (FITC) and albumin. RAW 264.7 cells were added to 6-well culture plates at 1 × 10 ⁶ cells / well / 3 ml and then cultured by adding 100 μg / ml of sample. After 48 hours of incubation, microspheres (average diameter, 300 nm) made of poly- (L) -lactic acid containing the fluorescent substance FITC were added and cultured again for 2 hours, and washed three times with PBS. Microspheres were removed. The amount of microspheres phenotyped by RAW 264.7 cells was analyzed by a flow cytometer (Becton-Dickinson).

Microspheres containing Ovalbumin and FITC were prepared by solvent evaporation [19]. OVA is dissolved in 3% polyvinyl alcohol (final, 4 mg / ml), poly (L-lactic acid) (PLG, final, 5%) and FITC (final, 5 mg / ml) are a mixture of acetone and ethanol ( 9: 1). 150 ml OVA solution and 30 ml PLG solution were slowly mixed and emulsified by continuous stirring overnight at room temperature. Hardened microspheres were collected by centrifugation at 300 g and washed twice with PBS.

Cytokine and Nitric Oxide Production

The amount of tumor necrosis factor (TNF) -α, interleukin (IL) -1β, and NO produced from the macrophage cell line RAW 264.7 by stimulation of the sample was quantified from the cell culture. Cells were added at 5 × 10 ⁵ cells / well / ml to 24-well culture plates, then MAP was added by dilution by concentration. After 48 hours of incubation, the contents of TNF-α and IL-1β contained in the culture supernatant were measured by using an R & D ELISA kit with an ELISA plate reader (Dynatech MR500) at a wavelength of 450 nm. The amount of nitrogen monoxide in the culture supernatant was 550 nm with an ELISA reader (Dynatech MR500) using Gries reagent (1% sulfanylamide / 0.1% naphthylenediamine dihydrochloride / 2.5% H ₃ PO ₄ ). And standard curve using sodium nitrite.

Anticancer activity

MAP (1 mg / mouse) was intraperitoneally injected daily for 6 days intraperitoneally of ICR mice. On day 4 after MAP injection, sarcoma 180 cells in passage culture were harvested in the abdominal cavity of ICR mice at 7 day intervals and transplanted intraperitoneally of mice receiving MAP (4 × 10 ⁵ cells / mouse). Four days after the injection of the sarcoma 180 cells, mice were killed, and 5 ml of PBS was injected into the abdominal cavity, and then the abdominal washing solution was collected. Erythrocytes of recovered peritoneal lavage fluid were removed with ACK lysis buffer and stained with FITC-bound anti-mouse CD45 mAb (Pharmingen) and analyzed by FACS caliber (Becton-Dickinson).

Removal of endotoxin

In order to confirm that the immunopotentiating activity of RAW 264.7 cells of MAP was not due to endotoxin contamination, all samples were tested with polymyxin B. All samples used in the experiment were filled in a bio-spin column (BIO-RAD) filled with 1 ml of Affi-Prep polymyxin substrate (BIO-RAD), centrifuged at 30 g for 1 minute, and 0.5 ml of sample was added. After standing at 18 ° C. for 18 hours, the sample was recovered by centrifugation at 30 g for 1 minute and used for the experiment. In order to confirm the function of the affinity column, LPS (10 mg / ml) was treated with Affi-Prep polymyxin substrate column in the same manner. Immunostimulatory activity after endotoxin removal of samples was confirmed by measuring TNF-α in RAW 264.7 cell culture.

result

Activation of Macrophage by MAP

To remove G2E1 and G2E1 proteins, which were obtained by treating aloe vera juice treated with cellulase with 80% ethanol, the immune activity of G2E1D obtained by passing an anion exchange resin in vitro was used to prepare RAW 264.7 cells, which are mouse macrophage cell lines. The experiment was carried out using.

As shown in FIG. 1A, G2E1D inhibited the proliferation of RAW 264.7 in a concentration dependent manner. The inhibitory effect of G2E1D on RAW 264.7 cells is not due to cytotoxicity but rather to differentiation of RAW 264.7 cells. RAW 264.7 cells are weakly adherent cells, but differentiation is induced by aloe polysaccharides and turned into cells with strong adhesion. In the raw 264.7 cells before the differentiation, no spread was observed on the cell surface, but the cytoplasm, which was differentiated by the sample and extended like a branch on the cell surface, was observed. RAW 264.7 cells, which are macrophage cell lines, have the property of inhibiting proliferation when they differentiate and become mature macrophages. Therefore, aloe polysaccharides are thought to have the effect of inhibiting proliferation by inducing differentiation of RAW 264.7 cells.                     

The immunopotentiation effect of G1E2D against macrophages can be confirmed by the concentration-dependent increase in TNF-α production (FIG. 1B), IL-1β production (FIG. 1C), and nitrogen monoxide secretion (FIG. 1D) by RAW 267.4 cells. there was. G2E1 has a significantly lower efficacy of activating macrophages than G2E1D from which proteins are removed, which is thought to be due to the presence of impurities in G2E1 that can reduce the activation of macrophages.

In order to confirm that the immunopotentiation effect of G2E1D against macrophages was not caused by contamination of LPS, the samples were treated with polymyxin B to test the effect of promoting TNF-α (FIG. 1E). At this time, LPS was also treated with polymyxin B in the same manner as the aloe sample and then used as a control. After LPS was treated with polymyxin B, the amount of TNF-α was significantly decreased compared with the pretreatment, but G2E1D was hardly decreased even after the polymyxin B treatment. Therefore, it could be confirmed that the immune enhancing effect of the aloe polysaccharide was not caused by endotoxin contamination.

Since the co-stimulatory molecule may be a criterion indicating the degree of activation of macrophages, the expression level of co-stimulatory molecules on the surface of RAW 264.7 cells by aloe polysaccharides was analyzed by flow cytometry. As shown in FIG. 2, G2E1D significantly increased the expression of CD40 and B7-1 at 100 μg / ml but showed little increase in G2E1 (solid line: expression level, dashed line: homozygous control).

One of the best indicators of macrophage activation is phagocytic activity, which increases with phagocytosis.                     

The phagocytosis of RAW 264.7 cells by aloe polysaccharide was measured using microspheres containing FITC and OVA. After 48 hours of incubation of RAW 264.7 cells and aloe polysaccharides, microspheres containing FITC (average diameter, 300 nm) were added and cultured again for 2 hours, and the amount of microspheres detected was measured by a flow cytometer (Becton-Dickinson). ). As shown in FIG. 3, G2E1D was found to significantly increase the phagocytosis of macrophages (solid line histogram: MAP-stimulated RAW 264.7 cells, shaded histogram: untreated RAW 264.7 cells).

Molecular Size-Macrophage Activity Efficacy Relationship

In order to investigate the molecular weight range of MAP that shows the best macrophage activity efficacy, G2E1DS3 (MW ≥400 KDa), G2E1DS2 (5 KDa ≤ MW ≤ 400 KDa), G2E1DS1, depending on molecular weight, were determined using Sephacryl column chromatography and ultrafiltration. Activity was measured by fractionation (MW <5 KDa) and then addition to RAW 264.6 cells. Macrophage activity efficacy was measured by adding MAP to RAW 264.7 cell culture as an indicator of growth inhibition (FIG. 4A), TNF-α production (FIG. 4B), and nitric oxide secretion promoting effect (FIG. 4C). As shown in FIG. 4, the G2E1DS2 fraction was found to have the best macrophage activity efficacy. The efficacy of the G1E2DS2 fraction was similar to that of G2E1D, but the G2E1DS1 and G2E1DS3 fractions showed very low activity compared to the G2E1DS2 fraction.

Anticancer Activity of MAP

The anticancer efficacy of MAP was tested using ICR species mice transplanted with sarcoma 180 cells. In this experiment, MAP was continuously intraperitoneally injected at a concentration of 1 mg / mouse for 6 days, and sarcoma 180 cells were implanted into the abdominal cavity of mice on the 4th day after the intraperitoneal injection of MAP. On day 4 of sarcoma 180 transplantation, cells intraperitoneally proliferating were harvested and stained intraperitoneally with FITC-bound anti mouse CD45 mAb and analyzed by a Becton-Dickinson. 5 shows the composition of cells in the abdominal cavity. Since CD45 expresses only hematopoietic derived cells (M2) excluding erythrocytes, the CD45 negative cells (M1) shown in FIG. 5 are sarcoma 180 cells. The anticancer efficacy of mice intraperitoneally administered with MAP was expressed as a reduction ratio for sarcoma 180 cells of the control group. As shown in Table 1, the G2E1D fraction was shown to have a strong anticancer effect (88.2% reduction), and the anticancer effect of this G2E1D fraction was due to the anticancer effect of the G2E1DS2 fraction (92.4% reduction). These results show that the macrophage activity identified in vitro and the anticancer activity identified in vivo are related.

Anticancer Activity of MAP on Sarcoma 180 Cells Dose (mg / mouse / day) Sarcoma 180 cells PEC Number (1X10 ⁵ ) % Inhibition ^b Number (1X10 ⁵ ) % Increase ^c Control - 3.90 - 1.10 - G2E1 ^a One 3.59 7.94 1.41 128 G2E1D One 0.51 86.92 4.49 408 G2E1DS1 One 3.32 14.87 1.68 152 G2E1DS2 One 0.33 91.53 4.67 424 G2E1DS3 One 3.28 15.89 1.72 156

a. Anticancer activity was tested as described in FIG. 5.

b. The% inhibition was calculated as follows: {C _N -T _N / C _N } × 100, where C _N and T _N represent the number of sarcoma 180 cells in each of the control and treatment groups.

c. The% increase was calculated as follows: {T _N -C _N / C _N } × 100, where C _N and T _N represent the number of PECs in each of the control and treatment groups.

The present invention confirmed the macrophage activation efficacy and anticancer efficacy of MAP, it was confirmed that the optimum molecular weight range having the best efficacy is in the range of 5 KDa to 400 KDa. Accordingly, the present invention provides an aloe composition that can be easily processed while exhibiting high physiological activity and having excellent macrophage activation efficacy and anticancer efficacy.

Claims (5)

A composition for anticancer containing processed aloe polysaccharides (MAP, Modified Aloe Polysaccharides) having a molecular weight of 5 to 400KDa. The composition of claim 1, wherein said aloe polysaccharide is obtained from aloe vera. A dietary supplement comprising a processed aloe polysaccharide (MAP) having a molecular weight of 5 to 400 KDa. The dry powder of aloe gel treated with cellulase was extracted using ethanol and then centrifuged to obtain aloe polysaccharide precipitate, which was then chromatographed into processed aloe polysaccharide (MAP) having a molecular weight of 5 KDa to 400 KDa. A process for producing a processed aloe polysaccharide (MAP) characterized by the above. Immunity-enhancing composition containing processed aloe polysaccharide (MAP) having a molecular weight of 5 to 400KDa.

Images